Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop
Approximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45% of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural his...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2006-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2006/238218 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849693877425930240 |
|---|---|
| author | Kymberly DS Watt Kelly Burak Marc Deschênes Les Lilly Denis Marleau Paul Marotta Andrew Mason Kevork M Peltekian Eberhard L Renner Eric M Yoshida for the Canadian Transplant Hepatology Outcomes Research Network |
| author_facet | Kymberly DS Watt Kelly Burak Marc Deschênes Les Lilly Denis Marleau Paul Marotta Andrew Mason Kevork M Peltekian Eberhard L Renner Eric M Yoshida for the Canadian Transplant Hepatology Outcomes Research Network |
| author_sort | Kymberly DS Watt |
| collection | DOAJ |
| description | Approximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45% of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural history, new complication risks and different treatment efficacy than nontransplant HCV patients. Every effort must be made to identify those patients at highest risk for progressive liver disease post-transplant. Recurrent HCV is an Achilles’ heel to transplant hepatology. The true natural history of this disease is only starting to unravel and many questions remain unanswered on the optimal management of these patients after liver transplantation. The present report summarizes the literature and ongoing research needs that are specific to HCV-related liver transplantation. |
| format | Article |
| id | doaj-art-4fcf1af69275448daed8bf773e112bac |
| institution | DOAJ |
| issn | 0835-7900 |
| language | English |
| publishDate | 2006-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-4fcf1af69275448daed8bf773e112bac2025-08-20T03:20:16ZengWileyCanadian Journal of Gastroenterology0835-79002006-01-01201172573410.1155/2006/238218Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology WorkshopKymberly DS Watt0Kelly Burak1Marc Deschênes2Les Lilly3Denis Marleau4Paul Marotta5Andrew Mason6Kevork M Peltekian7Eberhard L Renner8Eric M Yoshida9for the Canadian Transplant Hepatology Outcomes Research NetworkDalhousie University, Halifax, Nova Scotia, CanadaUniversity of Calgary Liver Unit, Calgary, Alberta, CanadaMcGill University Health Centre, Montreal, Quebec, CanadaUniversity of Toronto, University Health Network Liver Transplant Program, Toronto, Ontario, CanadaSaint Luc Hospital, University of Montreal, Montreal, Quebec, CanadaUniversity of Western Ontario Liver Unit, London Health Sciences, London, Ontario, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaDalhousie University, Halifax, Nova Scotia, CanadaUniversity of Manitoba, Health Sciences Centre, Winnipeg, Manitoba, CanadaUniversity of British Columbia, Vancouver, British Columbia, CanadaApproximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45% of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural history, new complication risks and different treatment efficacy than nontransplant HCV patients. Every effort must be made to identify those patients at highest risk for progressive liver disease post-transplant. Recurrent HCV is an Achilles’ heel to transplant hepatology. The true natural history of this disease is only starting to unravel and many questions remain unanswered on the optimal management of these patients after liver transplantation. The present report summarizes the literature and ongoing research needs that are specific to HCV-related liver transplantation.http://dx.doi.org/10.1155/2006/238218 |
| spellingShingle | Kymberly DS Watt Kelly Burak Marc Deschênes Les Lilly Denis Marleau Paul Marotta Andrew Mason Kevork M Peltekian Eberhard L Renner Eric M Yoshida for the Canadian Transplant Hepatology Outcomes Research Network Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop Canadian Journal of Gastroenterology |
| title | Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop |
| title_full | Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop |
| title_fullStr | Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop |
| title_full_unstemmed | Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop |
| title_short | Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop |
| title_sort | recurrent hepatitis c post transplantation where are we now and where do we go from here a report from the canadian transplant hepatology workshop |
| url | http://dx.doi.org/10.1155/2006/238218 |
| work_keys_str_mv | AT kymberlydswatt recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT kellyburak recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT marcdeschenes recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT leslilly recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT denismarleau recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT paulmarotta recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT andrewmason recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT kevorkmpeltekian recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT eberhardlrenner recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT ericmyoshida recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop AT forthecanadiantransplanthepatologyoutcomesresearchnetwork recurrenthepatitiscposttransplantationwherearewenowandwheredowegofromhereareportfromthecanadiantransplanthepatologyworkshop |